In the book, “China Rx: Exposing the Risks of America’s Dependence on China for Medicine,” co-author, Rosemary Gibson, explains the dangers of relying on one country as a source of vital medicines.
Hosts Robert and Kim Kiyosaki are joined by Rosemary Gibson to discuss how the United States can get out from under the dependence of China for drugs.
Here is a recent excerpt from a recent Op-Ed on Market Watch by Rosemary Gibson.
The perils of stockpiling
Some argue that the U.S. doesn’t need to make antibiotics. They believe the nation can simply stockpile supplies and rely on allies. But this is foolhardy. How would the Strategic National Stockpile be replenished in the middle of a pandemic, or if trade routes were blocked? And allies would likely need to keep antibiotic supplies for their own people.
As the U.S. seeks to build back better, what’s needed is a public-private partnership to help the nation prepare for the next pandemic or other crisis. The private market alone can’t fix this problem since U.S. companies can’t compete head-on with the full resources of the Chinese government. The harsh truth is that, without a federal partnership to invest in domestic antibiotic manufacturing capacity, U.S. producers don’t stand a chance.